KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Other Working Capital Changes (2020 - 2025)

Boston Scientific (BSX) has disclosed Other Working Capital Changes for 6 consecutive years, with -$61.0 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 458.82% to -$61.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.0 million through Dec 2025, down 66.67% year-over-year, with the annual reading at $42.0 million for FY2025, 66.67% down from the prior year.
  • Other Working Capital Changes hit -$61.0 million in Q4 2025 for Boston Scientific, down from -$5.0 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $140.0 million in Q1 2022 to a low of -$173.0 million in Q4 2022.
  • Historically, Other Working Capital Changes has averaged $23.7 million across 5 years, with a median of $6.0 million in 2023.
  • Biggest YoY gain for Other Working Capital Changes was 198.18% in 2022; the steepest drop was 1472.73% in 2022.
  • Year by year, Other Working Capital Changes stood at -$11.0 million in 2021, then plummeted by 1472.73% to -$173.0 million in 2022, then surged by 108.09% to $14.0 million in 2023, then rose by 21.43% to $17.0 million in 2024, then tumbled by 458.82% to -$61.0 million in 2025.
  • Business Quant data shows Other Working Capital Changes for BSX at -$61.0 million in Q4 2025, -$5.0 million in Q3 2025, and $115.0 million in Q2 2025.